Article thumbnail

Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy

By Pierre Blanchard, Laurent Quero, Vincent Pacault, Marie-Helene Schlageter, Valerie Baruch-Hennequin and Christophe Hennequin
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3338390
Provided by: PubMed Central

Suggested articles

Citations

  1. (2000). al: Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia. Ann Surg
  2. (2006). al: Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction.
  3. (2007). Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol
  4. (2005). Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
  5. (2000). et al: Activation of c-K-ras mutations in human gastrointestinal tumors. Gastroenterology
  6. (2000). et al: Mutations in zinc-binding domains of p53 as a prognostic marker of esophageal-cancer patients.
  7. (2008). KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
  8. (2007). Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol
  9. (1998). Safatle-Ribeiro AV, et al: p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer
  10. (1996). TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials
  11. (2007). TL: Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol
  12. (2010). TNM classification of malignant tumours. 7 edition.
  13. (2007). Triboulet JP: Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.